The expression of neutrophil gelatinase-associated lipocalin (NGAL) has been suggested to behave likea negative prognostic marker in stage I colorectal carcinoma. In the aim of clarifying whether its associationwith adverse outcome may descend from NGAL’s ability to regulate matrix metallo-proteinase-9(MMP-9), we analyzed the correlation, prognostic value, and association with neo-angiogenesis of NGALand MMP-9 immunohistochemical expression in a series of stage I colorectal carcinomas. A variableNGAL immunoexpression was demonstrated in 17 of the 48 analyzed cases with a significantly higherfrequency of positive cases among patients showing disease progression. NGAL expression was also positivelycorrelated with VEGF expression detected in the same cases. MMP-9 immunostaining was presentin the cytoplasm of the neoplastic cells in 30 cases; no significant correlations were evidenced with NGALexpression, as well as with the various clinico-pathological parameters or with progression of the colorectalcarcinomas. By contrast, NGAL expression was confirmed as a significant independent negativeprognostic marker related to a shorter disease-free survival in stage I colorectal carcinoma. Our preliminaryresults suggest that the association of NGAL with poor outcome might be independent from MMP-9regulation, thus highlighting its prognostic value in this neoplasia. If our findings are confirmed in furtheranalyses, NGAL assessment might be used in order to select those patients with a higher progression riskand to submit them to adjuvant therapies useful to prevent adverse outcome.

Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) prognostic value in stage I colorectal carcinoma / Barresi, V; Reggiani Bonetti, L; Di Gregorio, C; Vitarelli, E; PONZ DE LEON, Maurizio; Barresi, G.. - In: PATHOLOGY RESEARCH AND PRACTICE. - ISSN 0344-0338. - ELETTRONICO. - 207(2011), pp. 479-486.

I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Powered by IRIS-about IRIS-Utilizzo dei cookie

 Copyright © 2021